FRI0331 Apremilast for the treatment of behçet's syndrome: a phase ii randomized, placebo-controlled, double-blind study
Gülen Hatemi(Center for Rheumatology), Yusuf Yazıcı(Io Therapeutics (United States)), Cengiz Korkmaz(Eskişehir Osmangazi University), Melike Melikoğlu(Istanbul University-Cerrahpaşa), Cem Mat(Access to Wholistic and Productive Living Institute), Recep Tunç(Necmettin Erbakan University), Banu Öztürk(Selçuk University), R. Stevens(Bristol-Myers Squibb (Switzerland)), Hasan Yazıcı(Istanbul University), Lilia Pineda(Hofstra University), Kenneth Calamia(Jacksonville College), P. A. Merkel(University of Pennsylvania), Z. Liu(Cancer Research And Biostatistics)
Cited by 8
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
2018 update of the EULAR recommendations for the management of Behçet's syndrome
|Annals of the Rheumatic Diseases|2018|771
The Long-Term Mortality and Morbidity of Behçet Syndrome
|Medicine|2003|757
EULAR recommendations for the management of Behçet disease
|Annals of the Rheumatic Diseases|2008|721
A Controlled Trial of Azathioprine in Behçet's Syndrome
|New England Journal of Medicine|1990|646